缩写名/全名 |
MOL ONCOL
Molecular Oncology |
||||||||||||
ISSN号 | 1878-0261 | ||||||||||||
研究方向 | - | ||||||||||||
影响因子 | |||||||||||||
出版国家 | Netherlands | ||||||||||||
出版周期 | |||||||||||||
年文章数 | 173 | ||||||||||||
出版年份 | 0 | ||||||||||||
是否OA | Yes | ||||||||||||
审稿周期(仅供参考) | |||||||||||||
录用比例 | |||||||||||||
投稿链接 | |||||||||||||
投稿官网 | https://www.sciencedirect.com/journal/molecular-oncology | ||||||||||||
h-index | 63 | ||||||||||||
CiteScore |
|
||||||||||||
PubMed Central (PMC)链接 | http://www.ncbi.nlm.nih.gov/nlmcatalog?term=1878-0261%5BISSN%5D | ||||||||||||
中科院SCI期刊分区 ( 2018年新版本) |
|
||||||||||||
中科院SCI期刊分区 ( 2020年新版本) |
|
中国学者近期发表的论文 | |
1. | Six-gene Assay as a new biomarker in the blood of patients with colorectal cancer: establishment and clinical validation. Author: Shou X1, Li Y2, Hu W1, Ye T1, Wang G1, Xu F2, Sui M3, Xu Y1. Journal: Mol Oncol. 2019 Apr;13(4):781-791. doi: 10.1002/1878-0261.12427. Epub 2019 Feb 18. PubMed DOI |
2. | High affinity binding of H3K14ac through collaboration of bromodomains 2, 4 and 5 is critical for the molecular and tumor suppressor functions of PBRM1. Author: Liao L1,2, Alicea-Velázquez NL3,4, Langbein L1, Niu X5, Cai W1, Cho EA1,6, Zhang M2, Greer CB7, Yan Q2, Cosgrove MS3, Yang H1. Journal: Mol Oncol. 2019 Apr;13(4):811-828. doi: 10.1002/1878-0261.12434. Epub 2019 Feb 2. PubMed DOI |
3. | Detection of human papillomavirus in cases of head and neck squamous cell carcinoma by RNA-seq and VirTect. Author: Khan A1, Liu Q2, Chen X3,4, Stucky A3,4, Sedghizadeh PP3,4, Adelpour D3,4, Zhang X3,4,5, Wang K2, Zhong JF3,4. Journal: Mol Oncol. 2019 Apr;13(4):829-839. doi: 10.1002/1878-0261.12435. Epub 2019 Feb 23. PubMed DOI |
4. | Hypoxia-sensitive LINC01436 is regulated by E2F6 and acts as an oncogene by targeting miR-30a-3p in non-small cell lung cancer. Author: Yuan S1, Xiang Y1, Wang G1,2, Zhou M1,2, Meng G3, Liu Q1, Hu Z1, Li C1, Xie W1, Wu N1, Wu L1, Cai T1, Ma X1, Zhang Y1, Yu Z4, Bai L5, Li Y1. Journal: Mol Oncol. 2019 Apr;13(4):840-856. doi: 10.1002/1878-0261.12437. Epub 2019 Jan 30. PubMed DOI |
5. | Epigenetically modulated FOXM1 suppresses dendritic cell maturation in pancreatic cancer and colon cancer. Author: Zhou Z1, Chen H1, Xie R1, Wang H2, Li S1, Xu Q1, Xu N1, Cheng Q1, Qian Y1, Huang R1, Shao Z1, Xiang M1. Journal: Mol Oncol. 2019 Apr;13(4):873-893. doi: 10.1002/1878-0261.12443. Epub 2019 Feb 15. PubMed DOI |
6. | CA10 and CA11 negatively regulate neuronal activity-dependent growth of gliomas. Author: Tao B1, Ling Y2, Zhang Y3, Li S1,4, Zhou P1, Wang X1, Li B1, Jun Z1, Zhang W1, Xu C5, Shi J5, Wang L5, Zhang W6, Li S1. Journal: Mol Oncol. 2019 May;13(5):1018-1032. doi: 10.1002/1878-0261.12445. Epub 2019 Mar 20. PubMed DOI |
7. | TARBP2-mediated destabilization of Nanog overcomes sorafenib resistance in hepatocellular carcinoma. Author: Lai HH1,2, Li CW2, Hong CC3, Sun HY2,4, Chiu CF5, Ou DL6, Chen PS1,2. Journal: Mol Oncol. 2019 Apr;13(4):928-945. doi: 10.1002/1878-0261.12449. Epub 2019 Feb 22. PubMed DOI |
8. | The Ibr-7 derivative of ibrutinib exhibits enhanced cytotoxicity against non-small cell lung cancer cells via targeting of mTORC1/S6 signaling. Author: Zhang B1,2, Wang L1,2,3, Zhang Q1, Yan Y1,2, Jiang H4, Hu R4, Zhou X5, Liu X5, Feng J6, Lin N1,2. Journal: Mol Oncol. 2019 Apr;13(4):946-958. doi: 10.1002/1878-0261.12454. Epub 2019 Feb 22. PubMed DOI |
9. | Clinical factors associated with circulating tumor DNA (ctDNA) in primary breast cancer. Author: Zhou Y1, Xu Y2, Gong Y2, Zhang Y2, Lu Y2, Wang C1, Yao R1, Li P1, Guan Y2,3, Wang J3, Xia X2, Yang L2, Yi X2, Sun Q1. Journal: Mol Oncol. 2019 May;13(5):1033-1046. doi: 10.1002/1878-0261.12456. Epub 2019 Feb 6. PubMed DOI |
10. | WT1-interacting protein inhibits cell proliferation and tumorigenicity in non-small-cell lung cancer via the AKT/FOXO1 axis. Author: Wu Z1, Qiu M1,2, Mi Z3, Meng M1, Guo Y4, Jiang X5, Fang J6, Wang H1, Zhao J1, Liu Z1, Qian D1, Yuan Z1. Journal: Mol Oncol. 2019 May;13(5):1059-1074. doi: 10.1002/1878-0261.12462. Epub 2019 Feb 22. PubMed DOI |
|
|